Our Pipeline

At Servier Pharmaceuticals, our core business is focused in oncology where we believe that we have a unique opportunity to redefine how cancer is treated. We are committed to finding solutions that will address today's challenges. We aim to understand the needs of our patients at all points of their journey, while ensuring those who can benefit from our products have access to them. Advancing innovation for patients is at the heart of everything we do. Servier has significantly accelerated its investment in hard-to-treat cancers with more than 50% of research and development dedicated to deliver significant advances in areas of high unmet need that may truly move the needle for our patients. 

Servier’s pipeline includes many oncology assets at varying stages of clinical development

Hematological Malignancies

Molecule Area Primary Indication Partner Territory Phase

ONCASPAR®

(pegaspargase)

ALL
World
Registered
PRIMARY INDICATION
First Line Acute Lymphoblastic Leukemia
PARTNER
PARTNER
World
PRIMARY INDICATION
First Line Acute Lymphoblastic Leukemia
PARTNER
TERRITORY
World
First Line Acute Lymphoblastic Leukemia
World

ONCASPAR is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of pediatric and adult patients with first line acute lymphoblastic leukemia (ALL), ALL and hypersensitivity to native forms of L-asparaginase.

ONCASPAR is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of pediatric and adult patients with first line acute lymphoblastic leukemia (ALL), ALL and hypersensitivity to native forms of L-asparaginase.

ASPARLAS

(calaspargase pegol-mknl)

ALL
World
Registered
PRIMARY INDICATION
First Line Acute Lymphoblastic Leukemia
PARTNER
PARTNER
World
PRIMARY INDICATION
First Line Acute Lymphoblastic Leukemia
PARTNER
TERRITORY
World
First Line Acute Lymphoblastic Leukemia
World

ASPARLAS is indicated as a component of a multiagent chemotherapeutic regimen for the treatment of ALL in pediatric and young adult patients aged 1 month to 21 years.

ASPARLAS is indicated as a component of a multiagent chemotherapeutic regimen for the treatment of ALL in pediatric and young adult patients aged 1 month to 21 years.

TIBSOVO®

(ivosidenib tablets)

IDH1-AML
World except for China
Registered
PRIMARY INDICATION
Relapsed or Refractory Acute Myeloid Leukemia with a IDH1-mutation
PARTNER
Acquired by Servier from Agios Pharmaceuticals in 2021
PARTNER
World except for China
PRIMARY INDICATION
Relapsed or Refractory Acute Myeloid Leukemia with a IDH1-mutation
PARTNER
Acquired by Servier from Agios Pharmaceuticals in 2021
TERRITORY
World except for China
Relapsed or Refractory Acute Myeloid Leukemia with a IDH1-mutation
Acquired by Servier from Agios Pharmaceuticals in 2021
World except for China

TIBSOVO (ivosidenib tablets) is indicated in the U.S. for the treatment of acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA test in adult patients newly-diagnosed with AML who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy or adult patients with relapsed or refractory AML. 

TIBSOVO (ivosidenib tablets) is indicated in the U.S. for the treatment of acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA test in adult patients newly-diagnosed with AML who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy or adult patients with relapsed or refractory AML. 

IDHIFA ®

(enasidenib)

IDH2-mutant R/R AML
Bristol Myers Squibb
United States
Registered
PRIMARY INDICATION
Relapsed or Refractory Acute Myeloid Leukemia with a IDH2-mutation
PARTNER
Servier acquired U.S. co-promotion and milestone rights for IDHIFA in 2021 from Agios Pharmaceuticals
PARTNER
United States
PRIMARY INDICATION
Relapsed or Refractory Acute Myeloid Leukemia with a IDH2-mutation
PARTNER
Servier acquired U.S. co-promotion and milestone rights for IDHIFA in 2021 from Agios Pharmaceuticals
TERRITORY
United States
Relapsed or Refractory Acute Myeloid Leukemia with a IDH2-mutation
Servier acquired U.S. co-promotion and milestone rights for IDHIFA in 2021 from Agios Pharmaceuticals
United States

IDHIFA (enasidenib) is indicated for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.  

IDHIFA (enasidenib) is indicated for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.  

PIXURVI®

(pixantrone)

NHL
World
Registered
PRIMARY INDICATION
Relapsed or Refractory Non-Hodgkin Lymphoma
PARTNER
PARTNER
World
PRIMARY INDICATION
Relapsed or Refractory Non-Hodgkin Lymphoma
PARTNER
TERRITORY
World
Relapsed or Refractory Non-Hodgkin Lymphoma
World

PIXURVI is indicated for adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-Cell Lymphoma. PIXURVI is not registered in the United States.

PIXURVI is indicated for adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-Cell Lymphoma. PIXURVI is not registered in the United States.

MCL1 Inhibitor

AML
Novartis/Vernalis
World except for North America and Japan
Phase 1
PRIMARY INDICATION
Acute Myeloid Leukemia*
PARTNER
Novartis/Vernalis
PARTNER
World except for North America and Japan
PRIMARY INDICATION
Acute Myeloid Leukemia*
PARTNER
Novartis/Vernalis
TERRITORY
World except for North America and Japan
Acute Myeloid Leukemia*
Novartis/Vernalis
World except for North America and Japan

*In combination with BCL-2 Inhibitor

*In combination with BCL-2 Inhibitor

BCL-2 Inhibitor

R/R AML + NHL + MM
Novartis/Vernalis
World except for North America and Japan
Phase 1
PRIMARY INDICATION
Relapsed or Refractory Acute Myeloid Leukemia, Non-Hodgkin’s Lymphoma, Multiple Myeloma
PARTNER
Novartis/Vernalis
PARTNER
World except for North America and Japan
PRIMARY INDICATION
Relapsed or Refractory Acute Myeloid Leukemia, Non-Hodgkin’s Lymphoma, Multiple Myeloma
PARTNER
Novartis/Vernalis
TERRITORY
World except for North America and Japan
Relapsed or Refractory Acute Myeloid Leukemia, Non-Hodgkin’s Lymphoma, Multiple Myeloma
Novartis/Vernalis
World except for North America and Japan

BCL- 2 Inhibitor

R/R AML
Novartis/Vernalis
World except for North America and Japan
Phase 1
PRIMARY INDICATION
Relapsed or Refractory Acute Myeloid Leukemia
PARTNER
Novartis/Vernalis
PARTNER
World except for North America and Japan
PRIMARY INDICATION
Relapsed or Refractory Acute Myeloid Leukemia
PARTNER
Novartis/Vernalis
TERRITORY
World except for North America and Japan
Relapsed or Refractory Acute Myeloid Leukemia
Novartis/Vernalis
World except for North America and Japan

BCL-2 Inhibitor

R/R NHL
Novartis/Vernalis
World except for North America and Japan
Phase 1
PRIMARY INDICATION
Relapsed or Refractory Non-Hodgkin’s Lymphoma
PARTNER
Novartis/Vernalis
PARTNER
World except for North America and Japan
PRIMARY INDICATION
Relapsed or Refractory Non-Hodgkin’s Lymphoma
PARTNER
Novartis/Vernalis
TERRITORY
World except for North America and Japan
Relapsed or Refractory Non-Hodgkin’s Lymphoma
Novartis/Vernalis
World except for North America and Japan

BCL-2 Inhibitor

R/R MM
Novartis/Vernalis
World except for North America and Japan
Phase 1
PRIMARY INDICATION
Relapsed or Refractory Multiple Myeloma
PARTNER
Novartis/Vernalis
PARTNER
World except for North America and Japan
PRIMARY INDICATION
Relapsed or Refractory Multiple Myeloma
PARTNER
Novartis/Vernalis
TERRITORY
World except for North America and Japan
Relapsed or Refractory Multiple Myeloma
Novartis/Vernalis
World except for North America and Japan

BCL-2 Inhibitor

R/R CLL
Novartis/Vernalis
Phase 1
PRIMARY INDICATION
Relapsed or Refractory Chronic Lymphocytic Leukemia
PARTNER
Novartis/Vernalis
PARTNER
PRIMARY INDICATION
Relapsed or Refractory Chronic Lymphocytic Leukemia
PARTNER
Novartis/Vernalis
TERRITORY
Relapsed or Refractory Chronic Lymphocytic Leukemia
Novartis/Vernalis

Anti-CD19

R/R ALL Pediatric
Allogene Therapeutics
World except for the United States
Phase 1
PRIMARY INDICATION
Relapsed or Refractory Acute Lymphoblastic Leukemia Pediatric*
PARTNER
Allogene Therapeutics
PARTNER
World except for the United States
PRIMARY INDICATION
Relapsed or Refractory Acute Lymphoblastic Leukemia Pediatric*
PARTNER
Allogene Therapeutics
TERRITORY
World except for the United States
Relapsed or Refractory Acute Lymphoblastic Leukemia Pediatric*
Allogene Therapeutics
World except for the United States

​​​​​*Based on Cellectis TALEN® genome editing platform

​​​​​*Based on Cellectis TALEN® genome editing platform

Anti-CD19

R/R ALL Adult
Allogene Therapeutics
World except for the United States
Phase 1
PRIMARY INDICATION
Relapsed or Refractory Acute Lymphoblastic Leukemia Adult*
PARTNER
Allogene Therapeutics
PARTNER
World except for the United States
PRIMARY INDICATION
Relapsed or Refractory Acute Lymphoblastic Leukemia Adult*
PARTNER
Allogene Therapeutics
TERRITORY
World except for the United States
Relapsed or Refractory Acute Lymphoblastic Leukemia Adult*
Allogene Therapeutics
World except for the United States

​​​​​*Based on Cellectis TALEN® genome editing platform

​​​​​*Based on Cellectis TALEN® genome editing platform

Anti-CD19

R/R NHL
Allogene Therapeutics
World except for the United States
Phase 1
PRIMARY INDICATION
Relapsed or Refractory Non-Hodgkin’s Lymphoma*
PARTNER
Allogene Therapeutics
PARTNER
World except for the United States
PRIMARY INDICATION
Relapsed or Refractory Non-Hodgkin’s Lymphoma*
PARTNER
Allogene Therapeutics
TERRITORY
World except for the United States
Relapsed or Refractory Non-Hodgkin’s Lymphoma*
Allogene Therapeutics
World except for the United States

​​​​​*Based on Cellectis TALEN® genome editing platform

​​​​​*Based on Cellectis TALEN® genome editing platform

Ivosidenib

IDH1-mutant R/R MDS
World except for China
Phase 1
PRIMARY INDICATION
Relapsed or Refractory Myelodysplastic Syndrome
PARTNER
PARTNER
World except for China
PRIMARY INDICATION
Relapsed or Refractory Myelodysplastic Syndrome
PARTNER
TERRITORY
World except for China
Relapsed or Refractory Myelodysplastic Syndrome
World except for China

Ivosidenib

IDH1-mutant IC-Ineligible Frontline AML
Phase 3
PRIMARY INDICATION
First line Acute Myeloid Leukemia with IDH1 Mutation
PARTNER
PARTNER
PRIMARY INDICATION
First line Acute Myeloid Leukemia with IDH1 Mutation
PARTNER
TERRITORY
First line Acute Myeloid Leukemia with IDH1 Mutation

An ongoing phase 3 study, the AGILE trial is evaluating Ivosidenib + Azacitidine in adults with newly diagnosed AML and the IDH1 mutation who are not candidates for intensive treatment. 

An ongoing phase 3 study, the AGILE trial is evaluating Ivosidenib + Azacitidine in adults with newly diagnosed AML and the IDH1 mutation who are not candidates for intensive treatment. 

Ivosidenib

IDH1-mutant IC-Eligible Frontline AML
World except for China
Phase 3
PRIMARY INDICATION
Intensive Chemotherapy-Eligible Acute Myeloid Leukemia
PARTNER
PARTNER
World except for China
PRIMARY INDICATION
Intensive Chemotherapy-Eligible Acute Myeloid Leukemia
PARTNER
TERRITORY
World except for China
Intensive Chemotherapy-Eligible Acute Myeloid Leukemia
World except for China

HOVON 150 AML/AMLSG 29-18 is a phase 3, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in IC-eligible patients with newly diagnosed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with excess blasts-2, with an IDH1 or IDH2 mutation

HOVON 150 AML/AMLSG 29-18 is a phase 3, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in IC-eligible patients with newly diagnosed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with excess blasts-2, with an IDH1 or IDH2 mutation

Solid Tumors

Molecule Area Primary Indication Partner Territory Phase

LONSURF®

(trifluridine/tipiracil)

mCRC Third Line
Taiho Pharmaceutical Co.
World except for the United States
Registered
PRIMARY INDICATION
Third line metastatic Colorectal Cancer
PARTNER
Taiho Pharmaceutical Co.
PARTNER
World except for the United States
PRIMARY INDICATION
Third line metastatic Colorectal Cancer
PARTNER
Taiho Pharmaceutical Co.
TERRITORY
World except for the United States
Third line metastatic Colorectal Cancer
Taiho Pharmaceutical Co.
World except for the United States

LONSURF (trifluridine and tipiracil) is indicated for the treatment of adult patients with metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.

LONSURF (trifluridine and tipiracil) is indicated for the treatment of adult patients with metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.

LONSURF®

(trifluridine/tipiracil)

mCRC Third Line
Taiho Pharmaceutical Co.
World except for North America and Asia
Phase 2
PRIMARY INDICATION
Third line metastatic colorectal cancer with acquired EGFR resistance
PARTNER
Taiho Pharmaceutical Co.
PARTNER
World except for North America and Asia
PRIMARY INDICATION
Third line metastatic colorectal cancer with acquired EGFR resistance
PARTNER
Taiho Pharmaceutical Co.
TERRITORY
World except for North America and Asia
Third line metastatic colorectal cancer with acquired EGFR resistance
Taiho Pharmaceutical Co.
World except for North America and Asia

​​​​​*In combination with an EGFR inhibitor

​​​​​*In combination with an EGFR inhibitor

LONSURF®

(trifluridine/tipiracil)

mCRC First Line
Taiho Pharmaceutical Co.
World except for North America and Asia
Phase 3
PRIMARY INDICATION
First and third line metastatic Colorectal Cancer*
PARTNER
Taiho Pharmaceutical Co.
PARTNER
World except for North America and Asia
PRIMARY INDICATION
First and third line metastatic Colorectal Cancer*
PARTNER
Taiho Pharmaceutical Co.
TERRITORY
World except for North America and Asia
First and third line metastatic Colorectal Cancer*
Taiho Pharmaceutical Co.
World except for North America and Asia

*In combination with bevacizumab

*In combination with bevacizumab

LONSURF®

(trifluridine/tipiracil)

mGC Third Line
World except for North America and Asia
Registered
PRIMARY INDICATION
Third line metastatic Gastric Cancer
PARTNER
Taiho Pharmaceutical Co.
PARTNER
World except for North America and Asia
PRIMARY INDICATION
Third line metastatic Gastric Cancer
PARTNER
Taiho Pharmaceutical Co.
TERRITORY
World except for North America and Asia
Third line metastatic Gastric Cancer
Taiho Pharmaceutical Co.
World except for North America and Asia

LONSURF (trifluridine and tipiracil) is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.

LONSURF (trifluridine and tipiracil) is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.

ONIVYDE®

(Liposomal irinotecan)

mPAC post-gemcitabine
Ipsen
World except for the United States and Taiwan
Registered
PRIMARY INDICATION
Post-gemcitabine Metastatic Pancreatic Cancer
PARTNER
Ipsen
PARTNER
World except for the United States and Taiwan
PRIMARY INDICATION
Post-gemcitabine Metastatic Pancreatic Cancer
PARTNER
Ipsen
TERRITORY
World except for the United States and Taiwan
Post-gemcitabine Metastatic Pancreatic Cancer
Ipsen
World except for the United States and Taiwan

ONIVYDE (irinotecan liposome injection) is indicated, in combination with fluorouracil (5-FU) and leucovorin (LV), for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.

*In combination with 5-FU/leucovorin

ONIVYDE (irinotecan liposome injection) is indicated, in combination with fluorouracil (5-FU) and leucovorin (LV), for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.

*In combination with 5-FU/leucovorin

Vorasidenib

IDH-mutant Low-Grade Glioma
World
Phase 3
PRIMARY INDICATION
First line Low Grade Glioma
PARTNER
PARTNER
World
PRIMARY INDICATION
First line Low Grade Glioma
PARTNER
TERRITORY
World
First line Low Grade Glioma
World

The INDIGO Study is a Phase 3 clinical trial evaluating the safety and effectiveness of vorasidenib in people with Grade 2 low-grade gliomas with an IDH mutation. 

The INDIGO Study is a Phase 3 clinical trial evaluating the safety and effectiveness of vorasidenib in people with Grade 2 low-grade gliomas with an IDH mutation. 

Anti-PD-1, Anti-TIM3, Irinotecan Combo

Solid Tumors
Symphogen...
World
Phase 1
PRIMARY INDICATION
Second Line Cholangiocarcinoma
PARTNER
Symphogen is a subsidiary of Servier that serves as the antibody center of excellence. **
PARTNER
World
PRIMARY INDICATION
Second Line Cholangiocarcinoma
PARTNER
Symphogen is a subsidiary of Servier that serves as the antibody center of excellence. **
TERRITORY
World
Second Line Cholangiocarcinoma
Symphogen is a subsidiary of Servier that serves as the antibody center of excellence. **
World

*License option not yet exercised

*License option not yet exercised

Ivosidenib

Previously treated IDH1-mutant CCA
World except for China
PRIMARY INDICATION
Second line Cholangiocarcinoma with an IDH1-mutation
PARTNER
PARTNER
World except for China
PRIMARY INDICATION
Second line Cholangiocarcinoma with an IDH1-mutation
PARTNER
TERRITORY
World except for China
Second line Cholangiocarcinoma with an IDH1-mutation
World except for China

Ivosidenib was investigated in the ClarIDHy study, a global, randomized Phase 3 trial in previously treated IDH1 mutant cholangiocarcinoma patients who have documented disease progression following one or two systemic therapies in the advanced setting. 

Ivosidenib was investigated in the ClarIDHy study, a global, randomized Phase 3 trial in previously treated IDH1 mutant cholangiocarcinoma patients who have documented disease progression following one or two systemic therapies in the advanced setting. 

AG-270

MTAP-Deleted Pancreatic Cancer
World
Phase 1
PRIMARY INDICATION
Metastatic Pancreatic Cancer
PARTNER
PARTNER
World
PRIMARY INDICATION
Metastatic Pancreatic Cancer
PARTNER
TERRITORY
World
Metastatic Pancreatic Cancer
World

Anti-Met

MTAP-Deleted NSCLC
Phase 2
PRIMARY INDICATION
Non Small Cell Lung Cancer
PARTNER
PARTNER
PRIMARY INDICATION
Non Small Cell Lung Cancer
PARTNER
TERRITORY
Non Small Cell Lung Cancer

Anti-CD73

Various Solid Tumors
Phase 1
PRIMARY INDICATION
Various Solid Tumors
PARTNER
PARTNER
PRIMARY INDICATION
Various Solid Tumors
PARTNER
TERRITORY
Various Solid Tumors

More from Servier

Research & Development

We invest in innovative research and development through our own development or partnerships to best address the unmet needs of patients.

Learn More

Clinical Trials

We strive to have consistent and concise transparency throughout all our clinical trials and research and development for the benefit of our patients.

Learn More

About Us

Servier Pharmaceuticals is a privately held pharmaceutical company focused on oncology. Everything we do is to bring the promise of tomorrow to the patients we serve.

Learn More